Genetic pathways, prevention, and treatment of sporadic colorectal cancer

Oncoscience

Volumn 1, Issue 6, 2014, Pages 400-406

  Mundade, Rasika ^a   Imperiale, Thomas F ^b   Prabhu, Lakshmi ^a   Loehrer, Patrick J ^c   Lu, Tao ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Indiana Cancer Pavilion   (United States)

Author keywords

Colon cancer; Genetic pathway; Sporadic

Indexed keywords

EID: 84922134601     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.59     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. Cancer J. Clin 2009; 58: 225-49.
2. Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol. 2005; 23: 378-91.
3. Fleshman JW, Chung TP. The genetics of sporadic colon cancer. Seminars in Colon and Rectal Surgery. 2004; 13: 128-35.
4. Taylor DP, Burt RW, Williams MS, Haug PJ, Cannon-Albright LA. Population-based family history-specific risks for colorectal cancer: a constellation approach. Gastroenterology. 2010; 138: 877-85.
5. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011; 6: 479-507.
6. Slattery JL. Diet, lifestyle, and colon cancer. Semin Gastrointest Dis. 2000; 11: 1142-46.
7. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010; 138: 2059-72.
8. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature.1998; 396: 643-49.
9. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319: 525-32.
10. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993; 9: 138-41.
11. Kinzler KW, Vogelstein B. Colorectal tumors. Genetic Basis of Human Cancer. 2002; 2: 583-612.
12. Powell S, Zilz N, Beazer-Barclay Y et al. APC mutations occur early during colorectal tumorigenesis. Nature. 1992; 359: 235-37.
13. Esteller M, Sparks A, Toyota M et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000; 60: 4366-71.
14. Mann B, Gelos M, Siedow A et al. Target genes of betacatenin-T-cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A. 1999; 96: 1603-08.
15. Sparks A, Morin P, Vogelstein B et al. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998; 58: 1130-34.
16. Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol. 2012; 18: 5171: 80.
17. Pruitt K, Der C. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 2001; 171: 1-10.
18. Schubbert S1, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007; 4: 295-308.
19. Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61: 759-67.
20. Alberts J, Lewis R, Roberts W. Molecular Biology of the Cell. 5th ed. Garland Science, Taylor and Francis Group; New York, NY, USA: 2008. The molecular basis of cancer cell behaviour; pp. 1251-52.
21. Ogino S, Kawasaki T, Kirkner G, Ohnishi M, Fuchs C. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotypenegative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer. 2007; 7: 72-96.
22. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic Alterations in Colorectal Cancer. Gastrointest Cancer Res. 2012; 5: 19-27.
23. Geiersbach KB, Samowitz WS. Microsatellite instability and colorectal cancer. Arch Pathol Lab Med. 2011; 135: 1269-77.
24. Fang DC, Jass JR, Wang DX, Zhou XD, Luo YH, Young J. Infrequent loss of heterozygosity of APC/MCC and DCC genes in gastric cancer showing DNA microsatellite instability. J Clin Pathol. 1999; 52: 504-08.
25. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010; 138: 2073-87.
26. Jass JR, Young J, Leggett BA. Evolution of colorectal cancer: change of pace and direction. J Gastroenterol Hepatol. 2002; 17-26.
27. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010; 138: 2088-100.
28. Rustgi AK. BRAF: A Driver of the Serrated Pathway in Colon Cancer. Cancer Cell. 2013; 24: 1-2.
29. Ascierto PA1, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012; 10: 85-111.
30. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science. 1998; 280: 1036-37.
31. Gellad ZF, Provenzale D. Colorectal cancer: national and international perspective on the burden of disease and public health impact. Gastroenterology. 2010; 138: 2177-90.
32. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008; 134: 1570-95.
33. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149: 627-37.
34. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009; 104: 739-50.
35. Cancer screening-United States, 2010. MMWR Morb Mortal Wkly Rep. 2012; 61: 41-5.
36. Sharaf RN, Ladabaum U. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. Am J Gastroenterol. 2013; 108: 120-32.
37. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Costeffectiveness of colorectal cancer screening. Epidemiol Rev. 2011; 33: 88-100.
38. Parekh M, Fendrick AM, Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther. 2008; 27: 697-712.
39. Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ. Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med. 2010; 9: 7: e1000370.
40. Pignone MP, Russell L, Wagner JL, Editors. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. In: Press TNA, ed. Washington, D.C.: Institute of Medicine and National Research Council. 2005.
41. Colonoscopy versus fecal immunochekical testing in colorectal cancer screening. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A; COLONPREV Study Investigators. N Engl J Med. 2012; 366: 697-706.
42. URL: http://www.vaoutcomes.org/our_work/confirm/
43. Imperiale TF, RansohoffDF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM. Multitarget Stool DNA Testing for Colorectal-Cancer Screening. N Engl J Med. 2014; 370: 1287-97.
44. Magrini R, Bhonde MR, Hanski ML, Notter M, Scherübl H, Boland CR, Zeitz M, Hanski C. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer. 2002; 101: 23-31.
45. Akdeniz A, Kucukoztas N, Yalcin S, Akcali Z, Altundag O. Oxaliplatin-induced immune thrombocytopenia in a patient with colon cancer. Am Surg. 2011; 77: E9.
46. Ye J, Li L, Zhang Y, Zhang X, Ren D, Chen W. Recombinant salmonella-based 4-1BBL vaccine enhances T cell immunity and inhibits the development of colorectal cancer in rats: in vivo effects of vaccine containing 4-1BBL. Journal of Biomedical Science. 2013; 20: 8-25.
47. Oikonomou E, Pintzas A. Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies. Anticancer Res. 2006; 26: 1077-84.
48. Bass AJ, Lawrence MS, Brace LE, et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genet. 2011; 43: 964-68.
49. Leary RJ, Kinde I, Diehl F, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. 2010; 2: 1-15.